Cash Flow

v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities:    
Net income (loss) attributable to MariMed Inc. $ (1,895,142) $ (33,240)
Net income (loss) attributable to noncontrolling interests 63,233 141,626
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation 80,791 69,827
Equity compensation 572,807 19,295
Loss on debt settlements 1,213,841 18,278
Changes in operating assets and liabilities:    
Accounts receivable, net (668,561) 26,223
Deferred rents receivable (114,038) 219,126
Due from third parties (647,131) (22,486)
Due from related parties (391,886)
Other current assets (19,440) (319,451)
Other assets 36,142
Accounts payable (110,555) 297,535
Accrued expenses 616,213 153,179
Due to related parties (200,000) 626
Other liabilities (26,034)
Net cash provided by (used in) operating activities (1,071,840) 134,323
Cash flows from investing activities:    
Purchase of property and equipment (1,294,858) (1,806,655)
Interest on notes receivable 10,398 9,641
Net cash used in investing activities (1,284,460) (1,797,014)
Cash flows from financing activities:    
Proceeds from subscribed common stock 875,000 1,300,000
Issuance of common stock 600,000
Issuance of interest in subsidiary 150,000
Issuance (repayment) of promissory notes (500,000) 400,000
Proceeds from (payments of) mortgages payable, net 495,091 (28,515)
Exercise of stock options 39,000
Exercise of warrants 30,846
Distributions (64,275) (87,868)
Net cash provided by financing activities 1,475,662 1,733,617
Net change to cash and cash equivalents (880,638) 70,926
Cash and cash equivalents at beginning of period 1,290,231 569,356
Cash and cash equivalents at end of period 409,593 640,282
Supplemental disclosure of cash flow information:    
Cash paid for interest 291,912 71,853
Cash paid for taxes 12,596
Non-cash activities:    
Equity issued to settle debt $ 38,965

Source